作者: David A. Scheinberg , K. Christopher Garcia , Melissa Mathias , Jonathan Thomas Sockolosky
DOI:
关键词: CD47 、 T-cell receptor 、 Monoclonal 、 Myeloid leukemia 、 Acute lymphocytic leukemia 、 Antigen 、 Chemistry 、 Epitope 、 Cancer research 、 Major histocompatibility complex
摘要: The present disclosure describes the use of monoclonal T Cell Receptor mimic (TCRm) antibodies (abs) in combination with CD47 blockade to kill tumor cells, reduce burden and/or increase survival, particularly acute lymphocytic leukemia (ALL) and myeloid (AML) or when density peptide epitopes from previously undruggable intracellular proteins presented context major histocompatibility complex (MHC) molecules is lower than typical antigenic targets therapeutic solid liquid tumors a subject.